Envoy Medical, Inc.

Envoy Medical, Inc. is a hearing health company focused on developing innovative medical technologies across the hearing loss spectrum, aiming to shift the paradigm within the hearing industry by leveraging the ear's natural anatomy for sound capture ¹. The company's core business model revolves around the development and potential commercialization of fully implanted hearing devices. Revenue is primarily generated from the sale of Esteem FI-AMEI implants and replacement components, with future revenue expected to be driven by the Acclaim CI upon regulatory approval ². Revenue from product sales is recognized when the product is implanted or used in a surgical procedure ³. The company also sells prepaid battery replacement options and recognizes revenue from extended warranty plans ratably over time ⁴.

Envoy Medical's product portfolio includes two fully implanted hearing devices. The Esteem FI-AMEI, approved by the FDA in 2010, is a fully implanted active middle ear hearing device and remains the only FDA-approved fully implanted active hearing implant in the U.S. market ⁵. Despite its unique technology, the Esteem FI-AMEI has faced commercial challenges primarily due to its classification as a hearing aid by the Centers for Medicaid and Medicare Services (CMS), which has limited reimbursement coverage ⁶. Approximately 1,000 Esteem FI-AMEI devices have been implanted globally, providing over two decades of experience with the company's implantable sensor technology ⁷. New implantations of the Esteem FI-AMEI are not expected to exceed a few per year, and nominal revenue will continue from replacement sound processors for existing patients ⁸.

The company's primary focus has shifted to the investigational Acclaim CI, a fully implanted cochlear implant designed to address severe-to-profound sensorineural hearing loss not adequately treated by hearing aids ⁹. The Acclaim CI received Breakthrough Device Designation from the FDA in 2019 ¹⁰. Unlike partially implanted cochlear implants, the Acclaim CI is fully implanted, uses a piezoelectric sensor in the middle ear to capture sound, and does not require external components ¹¹. This design is believed to offer advantages such as increased daily usage (24-hours a day), hearing at night and in water, no external processor falling off during activities, and reduced battery maintenance through wireless charging ¹². The Acclaim CI battery is expected to last several days between charges and the battery pack is designed for replacement every 8-12 years via a less invasive surgical procedure ¹³. The company believes the Acclaim CI could significantly reduce overall costs by eliminating frequent replacement of external components and improve net healthcare outcomes through increased compliance and earlier adoption ¹⁴.

For the fiscal year ended December 31, 2025, Envoy Medical reported net revenues of $241 thousand ¹⁵, an increase of $16 thousand or 7.1% from $225 thousand in the prior year ¹⁶. Cost of goods sold increased to $874 thousand in 2025 from $742 thousand in 2024, a rise of $132 thousand or 17.8% ¹⁷. The company incurred an operating loss of $22,270 thousand in 2025, compared to an operating loss of $19,256 thousand in 2024 ¹⁸. The net loss for the year ended December 31, 2025, was $23,756 thousand, an increase from $20,795 thousand in 2024 ¹⁹. Diluted net loss per share attributable to common stockholders was $(1.23) in 2025, compared to $(1.49) in 2024 ²⁰. As of December 31, 2025, the company had cash of $3,739 thousand ²¹ and an accumulated deficit of $313,396 thousand ²². Total liabilities were $20,325 thousand ²³. Net cash used in operating activities was $18,201 thousand in 2025 ²⁴.

Year-over-year, net revenues increased by $16 thousand ²⁵. Research and development (R&D) expenses increased by $2,307 thousand, or 22.7%, to $12,486 thousand in 2025 from $10,179 thousand in 2024, reflecting the transition from development to the clinical trial phase ²⁶. Sales and marketing expenses decreased by $514 thousand, or 29.6%, to $1,220 thousand in 2025 from $1,734 thousand in 2024, primarily due to reduced legal fees for securing Esteem FI-AMEI insurance reimbursement ²⁷. General and administrative expenses increased by $1,105 thousand, or 16.2%, to $7,931 thousand in 2025 from $6,826 thousand in 2024, driven by a $315 thousand severance accrual for the former CFO and $299 thousand in increased consultant costs ²⁸. Interest expense, related party, increased by $774 thousand to $1,590 thousand in 2025 from $816 thousand in 2024 due to additional issuances of Term Loans ²⁹.

During the reported period, Envoy Medical completed enrollment of all 56 patients in its pivotal clinical study for the Acclaim CI on March 10, 2025 ³⁰. The FDA had approved the expansion of the study to its second and final stage on October 3, 2025 ³¹. The company also completed a public offering on February 12, 2026, raising approximately $30,000 thousand in gross proceeds and $27,730 thousand in net proceeds ³². On August 25, 2025, the company entered into a Satisfaction Agreement with GAT, forgiving all outstanding principal and accrued interest on Term Loans in exchange for a $100 thousand payment, resulting in a gain on extinguishment of $27,879 thousand recorded as a capital contribution ³³. On September 4, 2025, the company entered into a Voting and Extension Agreement with Glen Taylor, GAT, and an affiliated entity to extend the expiration date of the Term Loan Warrants to December 31, 2028 ³⁴.

Envoy Medical currently anticipates obtaining FDA approval for its Acclaim CI in late 2027 or early 2028, with the timeline potentially extending to the first half of 2028 if a panel review is requested by the FDA ³⁵. The company expects to continue incurring significant net losses for the foreseeable future, with research and development, sales and marketing, general and administrative expenses, and capital expenditures all projected to increase ³⁶. Management believes that existing cash balances combined with the initial net proceeds of approximately $27,730 thousand from the February 2026 Offering will be sufficient to fund ongoing operations, including the Acclaim CI clinical trials, into the second quarter of 2027, with potential additional funding from warrant exercises extending this timeframe ³⁷.

A major growth area for Envoy Medical is the commercialization of the Acclaim CI, which is designed to address severe-to-profound sensorineural hearing loss not adequately addressed by hearing aids ³⁸. The company estimates a potential market opportunity of over $80 billion in the United States alone for the adult cochlear implant market, based on an assumed selling price of $30,000 for a traditional cochlear implant ³⁹. The annual market opportunity for adult cochlear implants in the U.S. is estimated to exceed $750 million by 2026, with roughly 25,000-30,000 adults implanted annually ⁴⁰. The company believes the Acclaim CI is uniquely positioned to capture existing market share and a significant portion of the unserved market due to its fully implanted nature and lack of external components, which may reduce stigma and increase adoption ⁴¹. Furthermore, the Acclaim CI is expected to command a higher average selling price than existing partially implanted devices ⁴². International markets also present substantial opportunities, with approximately 50% of the hearing device market being international and significantly underserved ⁴³.

Operationally, the company's R&D expenses are expected to continue increasing as it advances the Acclaim CI through clinical trials and prepares for commercialization ⁴⁴. The pivotal clinical study for the Acclaim CI requires 56 total patients to be enrolled and followed for 12 months, with enrollment completed on March 10, 2025 ⁴⁵. Once 12-month follow-up data is collected for all patients, it will be analyzed and submitted to the FDA as part of a PMA application ⁴⁶. The company's go-to-market strategy post-PMA approval involves carefully selecting approximately 30 surgical sites initially, with plans to add an additional 30 sites annually until reaching roughly 150 active implanting sites ⁴⁷. Significant investments will be required for management team development, corporate infrastructure, manufacturing capabilities, and expansion of sales, distribution, and training networks ⁴⁸. The company also plans to invest resources in training and support for audiologists, who are crucial for identifying and referring potential Acclaim CI patients ⁴⁹.

Regarding capital allocation, the company intends to use the net proceeds from the February 2026 Offering, approximately $27,730 thousand, for working capital and other general corporate purposes to fund operations during the Acclaim CI clinical study ⁵⁰. The potential additional gross proceeds from the full exercise of Series A-1 Warrants and Series A-2 Warrants are approximately $18,000 thousand and $30,000 thousand, respectively, totaling $48,000 thousand ⁵¹. The company's R&D activities are central to its business model, and these expenses are expected to increase as the Acclaim CI progresses through later stages of clinical trials and development for commercialization ⁵². The company does not intend to pay cash dividends on shares of Class A Common Stock for the foreseeable future, instead retaining funds for business development and growth, though it will pay dividends on Series A Preferred Stock ⁵³.

The company explicitly flagged several structural headwinds and execution risks. The process of medical device development and regulatory approval is inherently uncertain, with no guarantee that the Breakthrough Device Designation will accelerate FDA approval or make it more likely ⁵⁴. Delays in FDA approval could allow competitors to offer similar products, necessitate significant additional capital, and potentially limit funds for corporate infrastructure and distribution development ⁵⁵. The successful commercialization of the Acclaim CI is dependent on governmental authorities and health insurers establishing coverage, adequate reimbursement levels, and favorable pricing policies, which are uncertain and can be time-consuming and costly to obtain ⁵⁶. The company operates in a very competitive business environment with major cochlear implant manufacturers having greater penetration, established relationships, and substantially greater financial and operational resources ⁵⁷. The company will need to make material investments in patient advertising, provider education and training, distribution capabilities, and physician strategic relationships to gain market share ⁵⁸. Furthermore, the company is dependent on third-party contract manufacturing organizations and material suppliers, making it vulnerable to supply shortages, increased costs, and quality or compliance issues, especially as production scales up ⁵⁹. The addressable market size and growth estimates for the Acclaim CI are based on assumptions that may prove incorrect, and technological or medical advances could provide alternatives ⁶⁰.

Envoy Medical faces substantial risks, including its status as an early-stage company with a history of losses, having incurred net losses of approximately $23.8 million ⁶¹ and $20.8 million ⁶² for the years ended December 31, 2025 and 2024, respectively, and an accumulated deficit of approximately $313.4 million ⁶³ as of December 31, 2025. The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern ⁶⁴. There is unpredictability in the medical device industry, the regulatory process for device approval, and the clinical development process, with no guarantee that the Acclaim CI will receive FDA approval on the planned timeline or at all ⁶⁵. Clinical failure can occur at any stage, and the company's limited clinical experience does not necessarily predict future results ⁶⁶. The successful commercialization of the Acclaim CI depends on obtaining coverage and adequate reimbursement levels from governmental authorities and health insurers, which is uncertain and could limit marketability and revenue generation ⁶⁷. The company operates in a highly competitive business environment with larger, more established competitors, and failure to compete successfully could adversely affect its business ⁶⁸. Dependence on the Acclaim CI for most future revenues makes the company vulnerable to commercialization failures or declines in demand ⁶⁹. Supply chain disruptions from events like wars, pandemics, or inflation could delay FDA trials or prevent sufficient production ⁷⁰. The company has identified material weaknesses in its internal control over financial reporting, including insufficient accounting personnel, lack of a formal risk assessment, and inadequate accounting policies and controls, which could lead to material misstatements ⁷¹. The market price of its Class A Common Stock has been and may continue to be extremely volatile, with a trading range as low as $0.36 ⁷² and as high as $11.46 ⁷³ since the Business Combination, and the company received a Nasdaq staff determination notice for failing to comply with the $1.00 minimum bid price requirement ⁷⁴.

Management's overall tone emphasizes the company's dedication to innovative medical technologies and its belief in leveraging the ear's natural anatomy for hearing, aiming to disrupt the hearing industry. A key strategic priority is the successful development and commercialization of the fully implanted Acclaim CI, which is currently in pivotal clinical trials. Management anticipates obtaining FDA approval for the Acclaim CI in late 2027 or early 2028, with a potential extension to the first half of 2028 if a panel review is requested ⁷⁵. Another strategic focus is to secure adequate funding for ongoing operations and clinical trials, with the February 2026 Offering providing approximately $27,730 thousand ⁷⁶ in net proceeds, expected to fund operations into the second quarter of 2027 ⁷⁷, with potential additional gross proceeds of $48,000 thousand ⁷⁸ from warrant exercises. Management also highlights the importance of establishing distribution channels and strategic relationships with clinics and healthcare professionals to capture market share for the Acclaim CI, acknowledging the need for material investments in patient advertising, provider education, and training ⁷⁹. The company is committed to supporting existing Esteem FI-AMEI patients and professionals, even as new implantations are expected to be minimal until reimbursement policy changes ⁸⁰.